Titterton Lewis H Jr has reported a significant acquisition of 8,000 shares in Anixa Biosciences Inc, a move that underscores his confidence in the company's future.
This acquisition, reported in a recent SEC filing, is notable as it highlights the ongoing activity among directors in the pharmaceutical sector, which is known for its innovation and competitive landscape.
Background
Titterton Lewis H Jr is a director at Anixa Biosciences Inc, a company focused on pharmaceutical preparations. The company operates under the CIK number 0000715446 and is based in San Jose, California. Anixa has been active in the market, as reflected in its recent filings, including multiple Form 4 submissions.
What the Filing Says
According to the filing dated October 26, 2026, Titterton acquired these shares on October 23, 2026, at a price of $2.98 per share. Following this transaction, he owns a total of 1,054,003 shares of Anixa Biosciences.
Impact
This acquisition may impact shareholder sentiment positively, as it reflects Titterton's belief in the company's potential. His role as a director adds weight to this transaction, potentially influencing other investors and stakeholders in the pharmaceutical industry.
What's Next
The filing does not say what happens next.
Transaction Details
The acquisition of 8,000 shares was executed under the transaction code 'P', indicating a purchase of the shares. Following this transaction, Titterton Lewis H Jr's total ownership in Anixa Biosciences has reached 1,054,003 shares, which reflects his significant stake in the company.
Company Overview
Anixa Biosciences Inc, incorporated in Delaware, operates in the pharmaceutical preparations sector, specifically classified under the SIC code 2834. The company is headquartered at 3150 Almaden Expressway, Suite 250, San Jose, California, and has a fiscal year that ends on October 31.
Reporting Owner Information
Titterton Lewis H Jr is identified as a director of Anixa Biosciences, and his address is listed as C/O Anixa Biosciences, Inc., at the same business address as the company. This aligns with his active role in the company's governance and decision-making processes.
Signature and Filing Date
The filing was signed by Titterton on October 26, 2026, confirming the transaction details and affirming his commitment to the company's future. The timely reporting of this acquisition is consistent with SEC regulations, ensuring transparency in corporate governance.